Referring Doctors

Dear Doctor:

Clinical research gives many patients the possibility to participate in a study in which they are offered an effective alternative for their pathologies.

In the event that you refer a patient to our center, we will maintain regular and fluid contact to keep you informed about your patient from the moment of evaluation. 

Studies recruiting patients

¡RECLUTANDO!

Metabolic acidosis in
kidney disease patients

TRICIDE STUDY

Phase III Study

The efficacy and safety of TRC-101 in delaying chronic kidney disease (CKD) in patients with metabolic acidosis are evaluated.

Research Product: TRC-101

TRC-101 is a hydrochloric acid (AC) binder that acts in the intestinal lumen, it is not absorbed and by binding AC it decreases its absorption and increases the concentration of bicarbonate in blood, correcting metabolic acidosis. TRC-101 does not have the limitations that sodium bicarbonate does (reference treatment), for example: complication of HTN, hydrosaline retention, etc; It is expected that more patients with metabolic acidosis may receive treatment in order to reduce the progression of chronic kidney disease, mortality, and increased muscle and bone deterioration typical of advanced stages of CKD.

To include patients in this study, they must have a creatinine clearance between 20 and 40 ml / min and bicarbonate ≤ 20 meq / l. In the event that the bicarbonate has not been measured lately, this practice can be carried out at the center.

¡RECLUTANDO!

Cardic
Insufficiency

DELIVER STUDY

Phase III Study

The efficacy and safety of dapagliflozin in the treatment of heart failure (HF) in patients with preserved left ventricular ejection fraction (≥40%) are evaluated.

Research Product: dapagliflozina

Dapagliflozin is already approved for the treatment of T2DM; it is currently being studied in heart failure patients with symptoms.

To include patients in this study, they must have symptoms of heart failure (at least functional class II dyspnea) and a preserved left ventricular ejection fraction (according to cardiac Doppler ultrasound or MRI).

Currently, patients who have been hospitalized for HF in the last month are being incorporated.

¡RECLUTANDO!

Anemia and
renal insufficiency

ASCEND STUDY

Phase III Study

The efficacy and safety of daprodustat in the treatment of anemia in patients with chronic kidney disease are evaluated.

Research Product: daprodustat

Daprodustat stimulates the production of erythropoietin by the kidney. The use of daprodustat is expected to be safer than the use of erythropoietin and the number of cardiovascular events to be less.

To include patients in this study, they must have anemia defined as a hemoglobin between 8 and 12 gr% and a creatinine clearance <60.

The study has a closing date for the inclusion of patients on September 26, 2020.

¡RECLUTANDO!

Rheumatoid arthritis
resistant to treatments

CONTRAST STUDY 1

Phase III Study

The objective of this study is to determine the efficacy and safety of GSK3196165 (otilimab) in combination with methotrexate (MTX) for the treatment of adults with moderate to severely active rheumatoid arthritis (RA) who have had an inadequate response to MTX. Otilimab (subcutaneously once weekly) is compared to tofacitinib (5 mg twice daily), a Janus kinase inhibitor (JAK) that is approved for the treatment of adults with moderately to severely active RA.

The efficacy and safety of GSK3196165 (otilimab) are evaluated in comparison with placebo and with tofacitinib.

Research Product: GSK3196165 (otilimab)

Otilimab is a monoclonal antibody that specifically binds to human GM-CSF and prevents its interaction with its receptor. GM-CSF is a pro-inflammatory cytokine that favors synovial inflammation in RA, since an increase in GM-CSF levels was observed in the synovial fluid of patients with RA and its receptor is expressed in synovial tissue. Elimination or neutralization of GM-CSF improves joint pain, function, and histological structure in patients with RA.

This study is aimed at patients with moderately to severely active RA, unresponsive to methotrexate.

¡RECLUTANDO!

Patients with
COPD and eosinophilia

208657 STUDY

Phase III Study

Mepolizumab as add-on treatment in patients with COPD characterized by frequent exacerbations and elevated eosinophil levels.

Research Product: mepolizumab

Mepolizumab is a monoclonal antibody that inhibits the ability of IL-5. It is administered subcutaneously once a month.   

Inclusion criteria

  • >  40 years
  • Blood eosinophil count> 300 cells
  • COPD diagnosis of more than one year.
  • FEV greater than 20% and less than 80% 
  • At least two exacerbations in the past year requiring systemic corticosteroids or antibiotics (or both) or a hospitalization for an exacerbation in the past year.
  • Triple therapy treatment: LABA / LAMA / ICS. 
  • Current or former smokers with a history of smoking ≥10 packs per year.

¡RECLUTANDO!

Rheumatoid arthritis
resistant to treatments

CONTRAST STUDY 3

Phase III Study

The objective of this study is to determine the efficacy and safety of GSK3196165, in combination with conventional synthetic disease-modifying antirheumatic drugs (ESCMAR), for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who have had a Inadequate response to biological DMARDs (b-DMARDs) and / or Janus kinase inhibitors (JAK). Two doses of GSK3196165 will be compared with sarilumab (200 mg subcutaneously every two weeks), an IL-6 inhibitor that is approved in many countries for the treatment of adults with moderately to severely active RA who have had an inadequate response. to b-DMARDs and / or JAK inhibitors.

Research Product: GSK3196165 (otilimab)

Otilimab is a monoclonal antibody that specifically binds to human GM-CSF and prevents its interaction with its receptor. GM-CSF is a pro-inflammatory cytokine that favors synovial inflammation in RA, since an increase in GM-CSF levels was observed in the synovial fluid of patients with RA and its receptor is expressed in synovial tissue. Elimination or neutralization of GM-CSF improves joint pain, function, and histological structure in patients with RA.

¡RECLUTANDO!

Patients with
COPD and eosinophilia

BOREAS STUDY

Phase III Study

The efficacy of dupilumab 300 mg every 2 weeks is evaluated. in patients with moderate or severe COPD.

Research Product: dupilumab

Dupilumab is a systemic targeted immunomodulatory agent that inhibits the Th2 pathway. It is a fully human monoclonal antibody (mAb) that targets the alpha subunit of the interleukin 4 receptor (IL-4Rα), a component of type I and type II IL-4 receptors, which mediate signaling by the IL-4 (both receptors) and by IL-13 (type II receptor).

Inclusion criteria

  • ≥40 to ≤80 years
  • Blood eosinophil count> 300 cells
  • COPD diagnosis
  • FEV between 30% and 70%
  • Documented history of ≥2 moderate exacerbations or ≥1 severe exacerbation within the year prior to enrollment
  • Triple therapy treatment: LABA / LAMA / ICS.
  • Current or former smokers with a history of smoking ≥10 packs per year.

¡RECLUTANDO!

Women
postmenopausal

STETRA STUDY

Phase III Study

The aim of the study is to measure the effect of treatment with estetrol 15 mg or 20 mg compared to placebo on the frequency and severity of moderate to severe vasomotor symptoms in postmenopausal women.

Research Product: estetrol

Inclusion criteria

Postmenopausal women ≥40 to ≤65 years of age with associated vasomotor symptoms (eg, hot flashes).

¡RECLUTANDO!

Pediatric patients
with asthma

HZA STUDY

Phase III-IV Study

To compare the efficacy of fluticasone furoate / vilanterol once daily with fluticasone furoate once daily in participants with asthma.

Patients between 5 and 11 years

Diagnosis of asthma older than six months

Prebronchodilator FEV between 50 and 90%

Treatment for stable asthma

¡RECLUTANDO!

Pacientes con DVAC
obstruido

ESTUDIO READY 1

Phase III Study

Objetivo: Evaluar la eficacia y seguridad de CUSA-081 (Reteplasa) vs Alteplasa vs placebo en el tratamiento de la disfunción de DAVC (Catéteres centrales)

Pacientes con DVAC obstruido con no más de 48 hs desde la detección de la obstrucción.
No puede ser DAVC utilizado para hemodiálisis.
No puede tener infección en el cateter.
No puede tener trastornos de la coagulación
No puede estar usando anticoagulantes

If you want us to contact you, complete the following form

Abrir Chat
Centro de Investigaciones Médicas MDP
Gracias por comunicarse con el Centro de Investigaciones Médicas , a la brevedad le estaremos respondiendo, deje sus datos para que podamos contactarlo